The JAK2 Exon 12 mutation test looks for specific genetic changes linked to myeloproliferative neoplasms (MPNs) — conditions where the bone marrow produces too many blood cells. It is most commonly used to help diagnose Polycythemia Vera, especially when the more common JAK2 V617F mutation has been tested and not detected. This test is typically ordered when blood counts, hemoglobin, or hematocrit are abnormally elevated without a clear secondary cause.
JAK2 Exon 12 mutations account for roughly 1–3% of Polycythemia Vera cases. JAK2 V617F is far more common, accounting for approximately 95% of cases — so Exon 12 testing is most relevant when V617F has already returned a negative result but clinical suspicion for PV remains.
How the test works
This is a PCR-based sequencing assay that examines DNA from circulating white blood cells and detects specific insertions and deletions in the exon 12 region of the JAK2 gene. It can identify mutations present in as little as approximately 5% of the sampled cells.
Important to note:
- Only specific regions of the JAK2 gene are analysed — mutations outside exon 12 will not be detected
- Results must always be interpreted alongside blood counts, clinical symptoms, and other laboratory findings
- A negative Exon 12 result does not exclude other myeloproliferative neoplasms or other JAK2 mutations
Why this test is ordered
This test is typically considered when:
- Haemoglobin, haematocrit, or red blood cell counts are persistently elevated without a clear secondary cause
- Polycythemia Vera is suspected but JAK2 V617F testing has returned a negative result
- Symptoms such as headaches, dizziness, itching after bathing, or unexplained fatigue are present alongside elevated blood counts
- A haematologist is working up a possible myeloproliferative neoplasm
JAK2 V617F testing should be considered first or alongside Exon 12 testing, as V617F accounts for the majority of JAK2-positive myeloproliferative cases.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →Frequently Asked Questions
What does a detected JAK2 Exon 12 mutation mean?
What does a not detected JAK2 Exon 12 result mean?
What is the difference between JAK2 Exon 12 and JAK2 V617F?
Is JAK2 Exon 12 an inherited mutation?
What conditions are associated with JAK2 Exon 12 mutations?
What happens after a detected JAK2 Exon 12 result?
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.
-
Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms
-
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
-
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
-
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion